Clinical Trial

. 2022 Sep 22;40(40):5798-5805.

doi: 10.1016/j.vaccine.2022.08.036. Epub 2022 Aug 31.

Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults

Affiliations

PMID: 36055877
PMCID: PMC9428332
DOI: 10.1016/j.vaccine.2022.08.036

Free PMC article

Clinical Trial

Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults

Joseph Fraiman et al. Vaccine. 2022.

Free PMC article

Abstract

Introduction: In 2020, prior to COVID-19 vaccine rollout, the Brighton Collaboration created a priority list, endorsed by the World Health Organization, of potential adverse events relevant to COVID-19 vaccines. We adapted the Brighton Collaboration list to evaluate serious adverse events of special interest observed in mRNA COVID-19 vaccine trials.

Methods: Secondary analysis of serious adverse events reported in the placebo-controlled, phase III randomized clinical trials of Pfizer and Moderna mRNA COVID-19 vaccines in adults (NCT04368728 and NCT04470427), focusing analysis on Brighton Collaboration adverse events of special interest.

Results: Pfizer and Moderna mRNA COVID-19 vaccines were associated with an excess risk of serious adverse events of special interest of 10.1 and 15.1 per 10,000 vaccinated over placebo baselines of 17.6 and 42.2 (95 % CI -0.4 to 20.6 and -3.6 to 33.8), respectively. Combined, the mRNA vaccines were associated with an excess risk of serious adverse events of special interest of 12.5 per 10,000 vaccinated (95 % CI 2.1 to 22.9); risk ratio 1.43 (95 % CI 1.07 to 1.92). The Pfizer trial exhibited a 36 % higher risk of serious adverse events in the vaccine group; risk difference 18.0 per 10,000 vaccinated (95 % CI 1.2 to 34.9); risk ratio 1.36 (95 % CI 1.02 to 1.83). The Moderna trial exhibited a 6 % higher risk of serious adverse events in the vaccine group: risk difference 7.1 per 10,000 (95 % CI -23.2 to 37.4); risk ratio 1.06 (95 % CI 0.84 to 1.33). Combined, there was a 16 % higher risk of serious adverse events in mRNA vaccine recipients: risk difference 13.2 (95 % CI -3.2 to 29.6); risk ratio 1.16 (95 % CI 0.97 to 1.39).

Discussion: The excess risk of serious adverse events found in our study points to the need for formal harm-benefit analyses, particularly those that are stratified according to risk of serious COVID-19 outcomes. These analyses will require public release of participant level datasets.

Keywords: Adverse events of special interest; Brighton Collaboration; COVID-19; COVID-19 vaccines; Coalition for Epidemic Preparedness Innovations; Moderna COVID-19 vaccine mRNA-1273; NCT04368728; NCT04470427; Pfizer-BioNTech COVID-19 vaccine BNT162b2; SARS-CoV-2; Safety Platform for Emergency vACcines; Serious adverse events; Vaccines; mRNA vaccines.

Conflict of interest statement

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Cited by

Exigency of Plant-Based Vaccine against COVID-19 Emergence as Pandemic Preparedness.
Chattopadhyay A, Jailani AAK, Mandal B. Chattopadhyay A, et al. Vaccines (Basel). 2023 Aug 9;11(8):1347. doi: 10.3390/vaccines11081347. Vaccines (Basel). 2023. PMID: 37631915 Free PMC article. Review.
Surfing Corona waves - instead of breaking them: Rethinking the role of natural immunity in COVID-19 policy.
Kalk A, Sturmberg J, Van Damme W, Brown GW, Ridde V, Zizi M, Paul E. Kalk A, et al. F1000Res. 2023 Aug 24;11:337. doi: 10.12688/f1000research.110593.2. eCollection 2022. F1000Res. 2023. PMID: 37576385 Free PMC article.
How Scientists View Vaccine Hesitancy.
Welch EW, Johnson TP, Chen T, Ma J, Islam S, Michalegko LF, Caldarulo M, Frandell A. Welch EW, et al. Vaccines (Basel). 2023 Jul 6;11(7):1208. doi: 10.3390/vaccines11071208. Vaccines (Basel). 2023. PMID: 37515024 Free PMC article.
Self-reported side effects following COVID-19 vaccination in athletes: A retrospective study.
Komici K, Verderosa S, D'Amico F, Guerra G. Komici K, et al. Hum Vaccin Immunother. 2023 Aug 1;19(2):2234788. doi: 10.1080/21645515.2023.2234788. Hum Vaccin Immunother. 2023. PMID: 37470390 Free PMC article.
Knife's edge: Balancing immunogenicity and reactogenicity in mRNA vaccines.
Lee J, Woodruff MC, Kim EH, Nam JH. Lee J, et al. Exp Mol Med. 2023 Jul;55(7):1305-1313. doi: 10.1038/s12276-023-00999-x. Epub 2023 Jul 10. Exp Mol Med. 2023. PMID: 37430088 Free PMC article. Review.

See all "Cited by" articles

References

1. Law B, Pim C. SO2-D2.1.3 Priority List of COVID-19 Adverse events of special interest [Internet]. 2021 Oct [cited 2022 Feb 17]. Available from: https://brightoncollaboration.us/wp-content/uploads/2021/11/SO2_D2.1.3_C....
1. Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603–2615. - PMC - PubMed
1. Baden L.R., El Sahly H.M., Essink B., Kotloff K., Frey S., Novak R., et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384(5):403–416. - PMC - PubMed
1. Sadoff J., Gray G., Vandebosch A.n., Cárdenas V., Shukarev G., Grinsztejn B., et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med. 2021;384(23):2187–2201. - PMC - PubMed
1. Health Canada. Search for clinical information on drugs and medical devices [Internet]. 2019 [cited 2021 Nov 9]. Available from: https://clinical-information.canada.ca/.

Publication types

Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

Associated data

Actions
- Search in PubMed
- Search in ClinicalTrials.gov
Actions
- Search in PubMed
- Search in ClinicalTrials.gov

LinkOut - more resources

Full Text Sources
Medical
- ClinicalTrials.gov
- MedlinePlus Health Information
Miscellaneous

NCI CPTAC Assay Portal
----------------------------------------------
Source

https://pubmed.ncbi.nlm.nih.gov/36055877/

The Tired Non-Conformist

Sunday, September 17, 2023